Effect of a Personalized Weaning Strategy on Weaning Success

NCT ID: NCT05719194

Last Updated: 2024-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

750 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-14

Study Completion Date

2026-03-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Weaning from mechanical ventilation is a daily challenge in intensive care units, as it can take up to 50% of the total duration of ventilation. The longer the duration of ventilation is, the more there is complication related with it.

Even when the spontaneous breathing trial is succeeded, 10 to 20% of extubations are failed and requires re-intubation.

There is two different ways to assess if the patient is capable of breathing by its own : T-piece which can be considered as hard to succeed (it can delay extubation for some patients) or pressure support ventilation with no PEEP which can be too easy and lead to an extubation too early.

Studies have identified risk factors of weaning induced pulmonary oedema wich is one of the main cause of failed extubation (up to 60%).

The purpose of P-WEAN is to evaluate whether a personalized strategy for weaning from mechanical ventilation, including daily search for weaning criteria and individualization of the weaning modality (T-piece or pressure support ventilation with zero PEEP) based on the existence of WIPO risk factors (obesity, COPD, heart disease) improves weaning success compared with usual practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Before the study begin, all participating centers will be randomized to determine the time between the control and the interventional period. Patients included in the study will not be randomized individually but will be managed either according to the standard of care of the service or according to the personalized strategy (according to the stepped wedge group of the center).

* Control period: Patients will be subjected to a weaning strategy in accordance with the usual care practices of the service (evaluation of the criteria of weanability, the modalities of the spontaneous breathing trial and extubation)
* Interventional period: Patients will undergo a protocolized and standardized weaning strategy, including a daily assessment of weaning criteria, and a weaning trial (PSV or T-piece) whose modalities will be defined by the presence or the absence of weaning induced pulmonary oedema risk factors. These are :
* Obesity defined as BMI greater than 30 kg/m²
* Suspected or known COPD
* Heart disease whether it is structural (hypertrophic, dilated, valvular), functional (diastolic or systolic dysfunction), ischemic, or dysrhythmic.

Step 1 :

Daily assessment of weaning criteria in accordance with the study protocol

Step 2 :

* No risk factors : spontaneous breathing trial for 1 hour with pressure support ventilation (setting a pressure support level of 5 to 8 cm of water with no PEEP)
* Risk factors : spontaneous breathing trial with a T-piece for 1 hour, measuring protein and hemoglobin by blood sample before and after the trial.

Step 3 : Reconnecting the patient for at least 30 minutes and extubation if the SBT is successful. If not, the optimization of cardiac function or fluid overload will be the responsibility of the clinician.

Decisions regarding the use of non-invasive ventilation (NIV) or high-flow nasal oxygenation, will be made based on each centre\'s expertise and current clinical practice to minimize interference with the study procedure. However, knowing the recent data and the possible superiority of NIV in preventing post-extubation respiratory failure for high risk patients, investigators will be strongly encouraged to prioritize the prophylactic use of NIV (over high-flow nasal oxygenation) after tracheal extubation.

Patients will be assessed by members of the investigating center\'s research team (under the supervision of the centre\'s investigators) at least daily during hospitalization in the ICU and until day 28 post-randomization, as well as at discharge and at 90 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Weaning Mechanical Ventilation Intubation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Pragmatic, controlled, multicenter, stepped wedge cluster randomized trial, considering centers as clusters.
Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors
Double blind is not possible as this study evaluate a care strategy. However, in order to limit evaluation bias, the methodologist will be blinded to the group.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard intervention

Group Type ACTIVE_COMPARATOR

Standard SBT

Intervention Type OTHER

Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.

Personalized intervention - WIPO risk factors vs no risk factors

Group Type EXPERIMENTAL

SBT with T-piece or PSV

Intervention Type OTHER

\- Risk factors of WIPO

Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.

Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.

Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.

If SBT failed : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.

\- No risk factors of WIPO

Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.

Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.

Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standard SBT

Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.

Intervention Type OTHER

SBT with T-piece or PSV

\- Risk factors of WIPO

Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.

Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.

Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.

If SBT failed : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.

\- No risk factors of WIPO

Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.

Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.

Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Resolution or improvement of the condition that led to intubation, as judged by the clinician in charge of the patient.
* Hemodynamic stability, defined as systolic blood pressure between 90 and 160 mmHg, heart rate less than 140 beats/min, without or with low doses of vasopressors.
* Glasgow score of 13 or greater and Richmond Agitation-Sedation Scale (RASS) score between -1 and +1.
* Respiratory stability defined as: oxygen saturation \> 90% with inspired oxygen fraction ≤ 0.5 and PEEP ≤ 8 cmH2O, respiratory rate \< 35/min, spontaneous tidal volume \> 5 mL/kg, and peak inspiratory pressure ≤ 15 cmH2O.
* Few secretions (\< 3 aspirations in the past 8 hours).
* Effective cough.
* Negative leak test (\>100 mL or \>10%).
* No surgery planned within 72 hours.
* Patients with a social security plan.

Exclusion Criteria

* Acute cerebral pathology requiring admission to intensive care and/or mechanical ventilation with tracheal intubation for neurological reasons (Glasgow score \<13 at the time of intubation or CT scan abnormality): hemorrhagic stroke without or with vascular malformation (aneurysm, arterio-venous malformation...), ischemic stroke, head trauma, cerebral anoxo-ischemia after cardiac arrest.
* Tetraplegic or paraplegic patients with lesion level higher than D8.
* Peripheral neuromuscular pathology (underlying myopathy or myasthenia).
* ICU's Neuromyopathy.
* Tracheostomy.
* Patients with a decision of non-reintubation or terminal intubation.
* Pregnant or lactating women.
* Patients already included in this study.
* Patients under guardianship, curatorship or safeguard of justice.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Clermont-Ferrand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jules Audard

Role: STUDY_CHAIR

CHU de Clermont-Ferrand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Bordeaux

Bordeaux, , France

Site Status RECRUITING

CHU de Clermont-Ferrand

Clermont-Ferrand, , France

Site Status RECRUITING

CHU de Grenoble

Grenoble, , France

Site Status RECRUITING

CHU de Lille

Lille, , France

Site Status RECRUITING

CHU de Lyon - Hôpital Lyon Sud

Lyon, , France

Site Status RECRUITING

CHU de Montpellier

Montpellier, , France

Site Status RECRUITING

CHU de Nantes

Nantes, , France

Site Status RECRUITING

CHU de Saint-Etienne

Saint-Etienne, , France

Site Status RECRUITING

CHU de Toulouse

Toulouse, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lise Laclautre

Role: CONTACT

+33473754963

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Matthieu BIAIS

Role: primary

Jules AUDARD

Role: primary

Thibaud CRESPY

Role: primary

Eric KIPNIS

Role: primary

Fabrice THIOLLIERE

Role: primary

Samir JABER

Role: primary

Alexandre BOURDIOL

Role: primary

Jérôme MOREL

Role: primary

Laure CROGNIER

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P-Wean PHRC IR 2020 AUDARD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.